Skip to main content

Smith + Nephew Plc Value Stock - Dividend - Research Selection

Smith and nephew

ISIN: GB0009223206 , WKN: 502816

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Smith & Nephew plc (SNN) Analyst/Investor Day Transcript

2025-12-12
Smith & Nephew plc (SNN) Analyst/Investor Day December 11, 2025 9:00 AM ESTCompany ParticipantsCraig BijouDeepak Nath - CEO & DirectorCathy...

Smith & Nephew plc (SNN) Analyst/Investor Day - Slideshow

2025-12-11
2025-12-11. The following slide deck was published by Smith & Nephew plc in conjunction with this event.

Smith & Nephew plc (SNN) Q3 2025 Sales Call Transcript

2025-11-06
Smith & Nephew plc (SNN) Q3 2025 Sales Call November 6, 2025 3:30 AM ESTCompany ParticipantsDeepak Nath - CEO & DirectorJohn Rogers - CFO &...

Smith & Nephew plc (SNN) Q3 2025 Sales/ Trading Statement Call - Slideshow

2025-11-06
2025-11-06. The following slide deck was published by Smith & Nephew plc in conjunction with this event.

Smith & Nephew: Expensive Valuations And Muted Growth May Dampen Upcoming Q3 Earnings Release

2025-11-05
Discover why Smith & Nephew (SNN) earns a 'Hold' rating amid valuation concerns and resistance levels. Click here to read my analysis of Smith & Nephew stock.

J&J lays out plan to splinter orthopedics business into separate company

2025-10-14
Johnson & Johnson is narrowing its focus again, nearly four years after peeling off its consumer health business. The health care giant said Tuesday that it will separate its orthopedics business into a standalone company known as DePuy Synthes. The move leaves J&J focused on its pharmaceutical and MedTech segments, which make prescription drugs, contact lenses and technology to treat cardiovascular disease and help with surgeries.

Smith+Nephew announces new category I CPT® code for its CARTIHEAL™ AGILI-C™ Cartilage Repair Implant

2025-10-09
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that the American Medical Association (AMA) CPT Editorial Panel has established a Category I Current Procedural Terminology (CPT) code for procedures involving its CARTIHEAL AGILI-C Cartilage Repair Implant, effective January 1, 2027. The new CPT code recognizes the clinical significance and growing adoption of the CARTIHEAL Implant, a single-stage, off-the-shelf solution for treating cartilage and osteochond

Smith & Nephew (LON:SN.) shareholders have earned a 14% CAGR over the last three years

2025-10-09
Thanks in no small measure to Vanguard founder Jack Bogle, it's easy buy a low cost index fund, which should provide...

SNN or SYK: Which Is the Better Value Stock Right Now?

2025-10-08
SNN vs. SYK: Which Stock Is the Better Value Option?

Orthopedic Digit Implants Market Report 2025-2033, with Profiles of Extremity Medical, Stryker, Zimmer, Smith & Nephew, Depuy, Arthrex, Acumed, Anika Therapeutics, VILEX, and Paragon 28

2025-10-08
Key opportunities in the orthopedic digit implants market include rising demand due to increasing prevalence of arthritis, technological advancements in biomaterials and implant design, and strategic partnerships among industry players. Additionally, growing preference for minimally invasive procedures and new market entrants offer significant potential. Orthopedic Digit Implants Market Orthopedic Digit Implants Market Dublin, Oct. 08, 2025 (GLOBE NEWSWIRE) -- The "Orthopedic Digit Implants Mark